Bosulif Drug Information
Generic name: BOSUTINIB
Uses of Bosulif
- BOSULIF is indicated for the treatment of:
- Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy.
- Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy. BOSULIF is a kinase inhibitor indicated for the treatment of
- Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Dosage & Administration of Bosulif
Recommended Dosage
The recommended dosage is taken orally once daily with food. Swallow tablets whole. Do not cut, crush, break or chew tablets.
Continue treatment with BOSULIF until disease progression or intolerance to therapy. Capsules may be swallowed whole. For patients who are unable to swallow a whole capsule(s), each capsule can be opened and the contents mixed with applesauce or yogurt.
Mixing the capsule contents with applesauce or yogurt cannot be considered a substitute of a proper meal. If a dose is missed beyond 12 hours, the patient should skip the dose and take the usual prescribed dose on the following day. As appropriate, the desired dose can be attained by combining different strengths of BOSULIF tablets or capsules.
Table 1: Dosing of BOSULIF for Pediatric Patients with Newly-Diagnosed CP Ph+ CML or with CP Ph+ CML with Resistance or Intolerance to Prior Therapy Preparation Instructions for BOSULIF Capsules Mixed with Applesauce or Yogurt For patients who are unable to swallow capsules, the contents of the capsules can be mixed with applesauce or yogurt. Remove the required number of capsules from the container to prepare the dose as instructed and the amount of either room temperature applesauce or yogurt in a clean container. Carefully open each capsule, add the entire capsule content of each capsule into the applesauce or yogurt, then mix the entire dose into the applesauce or yogurt.
Patients should immediately consume the full mixture in its entirety, without chewing. Do not store the mixture for later use. If the entire preparation is not swallowed do not take an additional dose.
Wait until the next day to resume dosing. Table 2: BOSULIF Escalation In clinical studies of adult patients with Ph+ CML, dose escalation by increments of 100 mg once daily to a maximum of 600 mg once daily was allowed in patients who did not achieve or maintain a hematologic, cytogenetic, or molecular response and who did not have Grade 3 or higher adverse reactions at the recommended starting dosage. Dose increases for insufficient response in pediatric patients with BSA ≥1.1 m 2 can be conducted similarly to adult recommendations in 100 mg increments.
The maximum dose in pediatric and adult patients is 600 mg once daily.
Dosage Adjustments for Non-Hematologic Adverse Reactions
- Elevated liver transaminases: If elevations in liver transaminases greater than 5×institutional upper limit of normal (ULN) occur, withhold BOSULIF until recovery to less than or equal to 2.5×ULN and resume at 400 mg once daily thereafter. If recovery takes longer than 4 weeks, discontinue BOSULIF. If transaminase elevations greater than or equal to 3×ULN occur concurrently with bilirubin elevations greater than 2×ULN and alkaline phosphatase less than 2×ULN (Hy's law case definition), discontinue BOSULIF.
- Diarrhea: For National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 3–4 diarrhea (increase of greater than or equal to 7 stools/day over baseline/pretreatment), withhold BOSULIF until recovery to Grade less than or equal to 1. BOSULIF may be resumed at 400 mg once daily. For other clinically significant, moderate or severe non-hematological toxicity, withhold BOSULIF until the toxicity has resolved, then consider resuming BOSULIF at a dose reduced by 100 mg taken once daily. If clinically appropriate, consider re-escalating the dose of BOSULIF to the starting dose taken once daily. In pediatric patients, dose adjustments for non-hematologic toxicities can be conducted similarly to adults, however the dose reduction increments may differ. For pediatric patients with BSA ≥1.1 m 2 or greater, reduce dose similarly to adults.
Dosage Adjustments for Myelosuppression
Dose reductions for severe or persistent neutropenia and thrombocytopenia are described below (Table 3). If cytopenia recurs, reduce dose by an additional 100 mg upon recovery and resume treatment, or by an additional 50 mg in pediatric patients with BSA <1.1 m 2 and resume treatment.
Dosage Adjustments for Renal Impairment or Hepatic Impairment The recommended starting doses for patients with renal and hepatic impairment are described in Table 4 below. Table 4: Dose Adjustments for Renal and Hepatic Impairment in Adult Patients Table 5: Dosage Adjustments for Renal and Hepatic Impairment in Pediatric Patients.
| BSA BSA=Body Surface Area | Newly-Diagnosed Recommended Dose (Once Daily) | Resistant or Intolerant Recommended Dose (Once Daily) |
|---|---|---|
| < 0.55 m 2 | 150 mg | 200 mg |
| 0.55 to < 0.63 m 2 | 200 mg | 250 mg |
| 0.63 to < 0.75 m 2 | 200 mg | 300 mg |
| 0.75 to < 0.9 m 2 | 250 mg | 350 mg |
| 0.9 to < 1.1 m 2 | 300 mg | 400 mg |
| ≥ 1.1 m 2 | 400 mg maximum starting dose (corresponding to maximum starting dose in adult indication) | 500 mg |
| Dose | Volume of Applesauce or Yogurt |
|---|---|
| 100 mg | 10 mL (2 teaspoons) |
| 150 mg | 15 mL (3 teaspoons) |
| 200 mg | 20 mL (4 teaspoons) |
| 250 mg | 25 mL (5 teaspoons) |
| 300 mg | 30 mL (6 teaspoons) |
| 350 mg | 30 mL (6 teaspoons) |
| 400 mg | 35 mL (7 teaspoons) |
| 450 mg | 40 mL (8 teaspoons) |
| 500 mg | 45 mL (9 teaspoons) |
| 550 mg | 45 mL (9 teaspoons) |
| 600 mg | 50 mL (10 teaspoons) |
| ANC Absolute Neutrophil Count less than 1000×10 6 /L or Platelets less than 50,000×10 6 /L | Withhold BOSULIF until ANC greater than or equal to1000×10 6 /L and platelets greater than or equal to 50,000×10 6 /L. Resume treatment with BOSULIF at the same dose if recovery occurs within 2 weeks. If blood counts remain low for greater than 2 weeks, upon recovery, reduce dose by 100 mg and resume treatment, or by 50 mg in pediatric patients with BSA <1.1 m 2 and resume treatment. If cytopenia recurs, reduce dose by an additional 100 mg upon recovery and resume treatment, or by an additional 50 mg in pediatric patients with BSA <1.1 m 2 and resume treatment. |
| Recommended Starting Dosage | |||
|---|---|---|---|
| [see Use in Specific Populations (8.6, 8.7) and Clinical Pharmacology (12.3) ]. | |||
| Newly-diagnosed chronic phase Ph+ CML | Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy | ||
| Normal renal and hepatic function | 400 mg daily | 500 mg daily | |
| Renal impairment | |||
| Creatinine clearance 30 to 50 mL/min | 300 mg daily | 400 mg daily | |
| Creatinine clearance less than 30 mL/min | 200 mg daily | 300 mg daily | |
| Hepatic impairment | |||
| Mild (Child-Pugh A), Moderate (Child-Pugh B) or Severe (Child-Pugh C) | 200 mg daily | 200 mg daily | |
| [see Use in Specific Populations (8.6, 8.7 ) and Clinical Pharmacology (12.3) ]. | ||||
| Newly-Diagnosed CP Ph+ CML Recommended Starting Dose (Once Daily) By Organ Function | ||||
| Pediatric Patients by Separated BSA BSA=Body Surface Area Band | Normal renal and hepatic function | Renal Impairment: Creatinine clearance 30 to 50 mL/min | Renal Impairment: Creatinine clearance less than 30 mL/min | Hepatic Impairment: Mild (Child-Pugh A), Moderate (Child-Pugh B) or Severe (Child-Pugh C) |
| Pediatric < 0.55 m 2 | 150 mg | 100 mg | 100 mg | 100 mg |
| Pediatric 0.55 to < 0.63 m 2 | 200 mg | 150 mg | 100 mg | 100 mg |
| Pediatric 0.63 to < 0.75 m 2 | 200 mg | 150 mg | 100 mg | 100 mg |
| Pediatric 0.75 to < 0.9 m 2 | 250 mg | 200 mg | 150 mg | 100 mg |
| Pediatric 0.9 to < 1.1 m 2 | 300 mg | 200 mg | 200 mg | 150 mg |
| Pediatric ≥ 1.1 m 2 | 400 mg | 300 mg | 200 mg | 200 mg |
| CP Ph+ CML with Resistance or Intolerance to Prior Therapy Recommended Starting Dose (Once Daily) By Organ Function | ||||
| Pediatric Patients by Separated BSA Band | Normal renal and hepatic function | Renal Impairment: Creatinine clearance 30 to 50 mL/min | Renal Impairment: Creatinine clearance less than 30 mL/min | Hepatic Impairment: Mild (Child-Pugh A), Moderate (Child-Pugh B) or Severe (Child-Pugh C) |
| Pediatric < 0.55 m 2 | 200 mg | 150 mg | 100 mg | 100 mg |
| Pediatric 0.55 to < 0.63 m 2 | 250 mg | 200 mg | 150 mg | 100 mg |
| Pediatric 0.63 to < 0.75 m 2 | 300 mg | 200 mg | 200 mg | 150 mg |
| Pediatric 0.75 to < 0.9 m 2 | 350 mg | 250 mg | 200 mg | 150 mg |
| Pediatric 0.9 to < 1.1 m 2 | 400 mg | 300 mg | 250 mg | 200 mg |
| Pediatric ≥ 1.1 m 2 | 500 mg | 400 mg | 300 mg | 200 mg |
Side Effects of Bosulif
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions, in ≥20% of adults with newly diagnosed CP Ph+ CML or CP, AP, or BP Ph+ CML with resistance or intolerance to prior therapy (N=814) were diarrhea (80%), rash (44%), nausea (44%), abdominal pain ( %). The most common adverse reactions, in ≥ %.
Adverse Reactions in Adult Patients With Newly-Diagnosed CP CML The clinical trial randomized and treated 533 patients with newly-diagnosed CP CML to receive BOSULIF 400 mg daily or imatinib 400 mg daily as single agents (Newly-Diagnosed CP CML Study). The safety population (received at least 1 dose of BOSULIF) included: • two hundred sixty-eight patients with newly-diagnosed CP CML had a median duration of BOSULIF treatment of 55 months (range: 0.3 to 60 months) and a median dose intensity of 394 mg/day. Serious adverse reactions occurred in 22% of patients with newly-diagnosed CP CML who received bosutinib.
Permanent discontinuation of bosutinib due to an adverse reaction occurred in 20% of patients with newly-diagnosed CP CML who received bosutinib. Adverse reactions which resulted in permanent discontinuation in > 2% of patients included hepatic dysfunction (9%). Dose modifications (dose interruption or reductions) of bosutinib due to an adverse reaction occurred in 68% of patients with newly-diagnosed CP CML.
The most common adverse reactions, in >20% of bosutinib-treated patients with newly-diagnosed CML (N= %). Adverse drug reactions are based on all-causality treatment-emergent adverse events. The commonality stratification is based on 'All Grades' under Total column. 'Grade 3', 'Grade 4' columns indicate maximum toxicity. 5 In the randomized study in patients with newly-diagnosed CP CML, one patient in the group treated with BOSULIF experienced a Grade 3 QTcF prolongation (>500 msec).
Patients with uncontrolled or significant cardiovascular disease including QT interval prolongation were excluded by protocol. Table 8 identifies the clinically relevant or severe Grade 3/4 laboratory test abnormalities for the Phase 3 newly-diagnosed CML safety population. Table 8: Select Laboratory Abnormalities (>20%) That Worsened From Baseline in Patients with Newly-Diagnosed CML in Bosutinib Adverse Reactions in Adult Patients With Imatinib-Resistant or -Intolerant Ph+ CP, AP, and BP CML The single-arm clinical trial enrolled patients with Ph+ CP, AP, or BP CML and with resistance or intolerance to prior therapy.
The safety population (received at least 1 dose of BOSULIF) included 546 CML patients: • two hundred eighty-four patients with CP CML previously treated with imatinib only who had a median duration of BOSULIF treatment of 26 months (range: 0.2 to 155 months), and a median dose intensity of 437 mg/day. • one hundred nineteen patients with CP CML previously treated with both imatinib and at least 1 additional tyrosine kinase inhibitor (TKI) who had a median duration of BOSULIF treatment of 9 months (range: 0.2 to 148 months) and a median dose intensity of 427 mg/day. • one hundred forty-three patients with advanced phase (AdvP) CML including 79 patients with AP CML and 64 patients with BP CML. The median dose intensity was 406 mg/day, and 456 mg/day, in the AP CML and BP CML cohorts, respectively. Serious adverse reactions occurred in 30% of patients in the safety population of the single-arm trial in patients with CML (N=546) who were resistant or intolerant to prior therapy.
Permanent discontinuation of bosutinib due to an adverse reaction occurred in 22% of patients with CML who were resistant or intolerant to prior therapy. Dose modifications (dose interruption or reductions) of bosutinib due to an adverse reaction occurred in 66% of patients with CML who were resistant or intolerant to prior therapy. The most common adverse reactions, in ≥20% of patients in the safety population of the single-arm trial in patients with CML (N=546) who were resistant or intolerant to prior therapy were diarrhea (83%), nausea ( %).
Table 9: Adverse Reactions (10% or Greater) in Patients With CML Who Were Resistant or Intolerant to Prior Therapy in Single-Arm Trial Based on a Minimum of 105 Months of Follow-up. Table 10 identifies the clinically relevant or severe Grade 3/4 laboratory test abnormalities for the safety population of the study in patients with CML who were resistant or intolerant to prior therapy based on long-term follow-up. Table 10: Number (%) of Patients With Clinically Relevant All Grade or Grade 3/4 Laboratory Test Abnormalities in the Safety Population of the Study of Patients With CML Who Were Resistant or Intolerant to Prior Therapy Based on a Minimum of Pediatric Patients with Newly-Diagnosed CP Ph+ CML or CP Ph+ CML that is Resistant or Intolerant to Prior Therapy The safety of BOSULIF was evaluated in BCHILD, a single-arm trial for the treatment of pediatric patients aged 1 year and older with newly-diagnosed CP Ph+ CML or in patients with CP Ph+ CML who are resistant or intolerant to prior therapy.
Patients received BOSULIF n = orally once daily until disease progression or unacceptable toxicity. The median time on treatment with BOSULIF was 12.2 months (range, 0.2 to 60.9 months). Among patients who received BOSULIF, 77.6% were exposed for 6 months or longer and 51% were exposed for one year or longer.
The most common adverse reactions, in ≥20% of BOSULIF-treated pediatric patients were diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, hepatic dysfunction, headache, pyrexia, decreased appetite, and constipation. Table 11 summarizes the adverse reactions in BCHILD. Table 11: Adverse Reactions (10% or Greater) in Pediatric Patients with Newly Diagnosed CP Ph+ CML or CP Ph+ CML Resistant or Intolerant to Prior Therapy Who Received BOSULIF in BCHILD 2 The most common laboratory abnormalities that worsened from baseline in ≥20% of patients were creatinine increased, alanine aminotransferase increased, white blood cell count decreased, aspartate aminotransferase increased, platelet count decreased, glucose increased, calcium decreased, hemoglobin decreased, neutrophil count decreased, lymphocyte count decreased, serum amylase increased and CPK increased.
Table 12 summarizes laboratory test abnormalities in BCHILD. Table 12: Laboratory Abnormalities (≥ 20%) That Worsened From Baseline in Pediatric Patients with Newly-Diagnosed CP Ph+ CML or CP Ph+ CML Resistant or Intolerant to Prior Therapy Who Received BOSULIF in BCHILD 0 Additional Adverse Reactions From Multiple Clinical Trials The following adverse reactions were reported in patients in clinical trials with BOSULIF (less than 10% of BOSULIF-treated patients). They represent an evaluation of the adverse reaction data from all 1372 patients with leukemia who received at least 1 dose of single-agent BOSULIF.
These adverse reactions are presented by system organ class and are ranked by frequency. These adverse reactions are included based on clinical relevance and ranked in order of decreasing seriousness within each category. Blood and Lymphatic System Disorders: 0.1% and less than 1% - Febrile neutropenia Cardiac Disorders: 1% and less than 10% - Cardiac ischemia (includes Acute coronary syndrome, Acute myocardial infarction, Angina pectoris, Angina unstable, Arteriosclerosis coronary artery, Coronary artery disease, Coronary artery occlusion, Coronary artery stenosis, Myocardial infarction, Myocardial ischemia, Troponin increased), Pericardial effusion, Cardiac failure (includes Cardiac failure, Cardiac failure acute, Cardiac failure chronic, Cardiac failure congestive, Cardiogenic shock, Cardiorenal syndrome, Ejection fraction decreased, Left ventricular failure); 0.1% and less than 1% - Pericarditis Ear and Labyrinth Disorders: 1% and less than 10% - Tinnitus Endocrine Disorders: 1% and less than 10% - Hypothyroidism; 0.1% and less than 1% - Hyperthyroidism Gastrointestinal Disorders: 1% and less than 10% - Gastritis, Pancreatitis (includes Edematous pancreatitis, Pancreatic enzymes increased, Pancreatitis, Pancreatitis acute, Pancreatitis chronic), Gastrointestinal hemorrhage (includes Anal hemorrhage, Gastric hemorrhage, Gastrointestinal hemorrhage, Intestinal hemorrhage, Lower gastrointestinal hemorrhage, Rectal hemorrhage, Upper gastrointestinal hemorrhage) General Disorders and Administrative Site Conditions: 1% and less than 10% - Pain Immune System Disorders: 1% and less than 10% - Drug hypersensitivity; 0.1% and less than 1% - Anaphylactic shock Infections and Infestations: 1% and less than 10% - Bronchitis Investigations: 1% and less than 10% - Electrocardiogram QT prolonged (includes Electrocardiogram QT prolonged, Long QT syndrome) Metabolism and Nutrition Disorders: 1% and less than 10% - Dehydration Musculoskeletal and Connective Tissue Disorders: 1% and less than 10% - Myalgia Nervous System Disorders: 1% and less than 10% - Dysgeusia Renal and Urinary Disorders: 1% and less than 10% - Acute kidney injury, Renal impairment, Renal failure Respiratory, Thoracic and Mediastinal Disorders: 1% and less than 10% - Pulmonary hypertension (includes Pulmonary hypertension, Pulmonary arterial hypertension, Pulmonary arterial pressure increased); 0.1% and less than 1% - Acute pulmonary edema (includes Acute pulmonary edema, Pulmonary edema), Interstitial lung disease, Respiratory failure Skin and Subcutaneous Disorders: 0.1% and less than 1% - Erythema multiforme, Cutaneous vasculitis
Postmarketing Experience
The following additional adverse reactions have been identified during post-approval use of BOSULIF. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and Lymphatic System Disorders: Thrombotic microangiopathy Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome
| Bosutinib 400 mg Chronic Phase CML (N=268) | Imatinib 400 mg Chronic Phase CML (N=265) | ||||
|---|---|---|---|---|---|
| System Organ Class | Preferred Term | All Grades % | Grade 3/4 % | All Grades % | Grade 3/4 % |
| Gastrointestinal disorders | Diarrhea | 75 | 9 | 40 | 1 |
| Abdominal pain Abdominal pain includes the following preferred terms: Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Abdominal tenderness, Dyspepsia, Epigastric discomfort, Gastrointestinal pain. | 39 | 2 | 27 | 1 | |
| Nausea | 37 | 0 | 42 | 0 | |
| Vomiting | 21 | 1 | 20 | 0 | |
| Constipation | 13 | 0 | 6 | 0 | |
| Hepatobiliary disorders | Hepatic dysfunction Hepatic dysfunction includes the preferred terms: Alanine aminotransferase increased, Aspartate aminotransferase, Aspartate aminotransferase increased, Bilirubin conjugated increased, Blood alkaline phosphatase increased, Blood bilirubin increased, Drug-induced liver injury, Gamma-glutamyltransferase increased, Hepatic enzyme increased, Hepatic steatosis, Hepatitis, Hepatitis toxic, Hepatocellular injury, Hepatotoxicity, Hyperbilirubinemia, Jaundice, Liver disorder, Liver function test increased, Ocular icterus, Transaminases increased. | 45 | 27 | 15 | 4 |
| Skin and subcutaneous tissue disorders | Rash Rash includes the following preferred terms: Acne, Blister, Dermatitis, Dermatitis acneiform, Dermatitis bullous, Dermatitis exfoliative generalized, Drug reaction with eosinophilia and systemic symptoms, Dyshidrotic eczema, Eczema, Eczema asteatotic, Erythema, Erythema nodosum, Genital rash, Lichen planus, Perivascular dermatitis, Photosensitivity reaction, Psoriasis, Rash, Rash erythematous, Rash macular, Rash maculo-papular, Rash papular, Rash pruritic, Rash pustular, Rash vesicular, Seborrhoeic keratosis, Skin discoloration, Skin exfoliation, Skin hypopigmentation, Skin irritation, Skin lesion, Stasis dermatitis. | 40 | 2 | 30 | 2 |
| Pruritus | 11 | <1 | 4 | 0 | |
| General disorders and administration-site conditions | Fatigue Fatigue includes the following preferred terms: Asthenia, Fatigue, Malaise. | 33 | 1 | 30 | <1 |
| Pyrexia | 17 | 1 | 11 | 0 | |
| Edema Edema includes the following preferred terms: Eye edema, Eyelid edema, Face edema, Edema, Edema peripheral, Orbital edema, Periorbital edema, Periorbital swelling, Peripheral swelling, Swelling, Swelling face, Swelling of eyelid, Swollen tongue. | 15 | 0 | 46 | 2 | |
| Infections and infestations | Respiratory tract infection Respiratory tract infection includes the following preferred terms: Nasopharyngitis, Respiratory tract congestion, Respiratory tract infection, Respiratory tract infection viral, Upper respiratory tract infection. | 27 | 1 | 25 | <1 |
| Nervous system disorders | Headache | 22 | 1 | 15 | 1 |
| Musculoskeletal and connective tissue disorders | Arthralgia | 18 | 1 | 18 | <1 |
| Back pain | 12 | <1 | 9 | <1 | |
| Respiratory, thoracic, and mediastinal disorders | Cough | 11 | 0 | 10 | 0 |
| Dyspnea | 11 | 1 | 6 | 1 | |
| Metabolism and nutrition disorders | Decreased appetite | 11 | <1 | 6 | 0 |
| Vascular disorders | Hypertension Hypertension* includes the preferred terms: Blood pressure systolic increased, Hypertension, Hypertensive crisis, Hypertensive heart disease, Retinopathy hypertensive. | 10 | 5 | 11 | 5 |
| Bosutinib N=268 % | Imatinib N=265 % | |||
|---|---|---|---|---|
| All Grade | Grade 3–4 | All Grade | Grade 3–4 | |
| Abbreviations: ALT=alanine aminotransferase; AST=aspartate aminotransferase; CML=chronic myelogenous leukemia; SGPT=serum glutamic-pyruvic transaminase; SGOT=serum glutamic-oxaloacetic transaminase; N/n=number of patients; ULN=upper limit of normal. Graded using CTCAE v 4.03 | ||||
| Hematology Parameters | ||||
| Platelet Count decreased | 68 | 14 | 60 | 6 |
| Absolute Neutrophil Count decreased | 42 | 9 | 65 | 20 |
| Hemoglobin decreased | 89 | 9 | 90 | 7 |
| White Blood Cell Count decreased | 50 | 6 | 70 | 8 |
| Lymphocyte Count decreased | 84 | 12 | 82 | 14 |
| Biochemistry Parameters | ||||
| SGPT/ALT increased | 68 | 26 | 28 | 3 |
| SGOT/AST increased | 56 | 13 | 29 | 3.4 |
| Lipase increased | 53 | 19 | 35 | 8 |
| Phosphorus decreased | 54 | 9 | 69 | 21 |
| Amylase increased | 32 | 3.4 | 18 | 2.3 |
| Alkaline Phosphatase increased | 41 | 0 | 43 | 0.4 |
| Calcium decreased | 55 | 1.5 | 57 | 1.1 |
| Glucose increased | 57 | 3 | 65 | 3.4 |
| Creatine Kinase increased | 36 | 3 | 65 | 5 |
| Creatinine increased | 94 | 1.1 | 98 | 0.8 |
| CP CML (N=403) | AdvP CML (N=143) | ||||
|---|---|---|---|---|---|
| System Organ Class | Preferred Term | All Grades % | Grade 3/4 % | All Grades % | Grade 3/4 % |
| ADR Definition | |||||
| Gastrointestinal disorders | Diarrhea | 85 | 10 | 76 | 4 |
| Abdominal pain Abdominal pain includes the following preferred terms: Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Abdominal tenderness, Dyspepsia, Epigastric discomfort, Gastrointestinal pain, Hepatic pain. | 49 | 2 | 36 | 7 | |
| Nausea | 47 | 1 | 48 | 2 | |
| Vomiting | 38 | 3 | 43 | 3 | |
| Constipation | 15 | <1 | 17 | 1 | |
| Skin and subcutaneous tissue disorders | Rash Rash includes the following preferred terms: Acarodermatitis, Acne, Angular cheilitis, Blister, Dermatitis, Dermatitis acneiform, Dermatitis psoriasiform, Drug eruption, Eczema, Eczema asteatotic, Erythema, Erythema annulare, Exfoliative rash, Lichenoid keratosis, Palmar erythema, Photosensitivity reaction, Pigmentation disorder, Psoriasis, Pyoderma gangrenosum, Pyogenic granuloma, Rash, Rash erythematous, Rash generalised, Rash macular, Rash maculo-papular, Rash pruritic, Rash pustular, Seborrhoeic dermatitis, Seborrhoeic keratosis, Skin depigmentation, Skin discoloration, Skin disorder, Skin exfoliation, Skin hyperpigmentation, Skin hypopigmentation, Skin irritation, Skin lesion, Skin plaque, Skin toxicity, Stasis dermatitis. | 48 | 9 | 42 | 5 |
| Pruritus | 12 | 1 | 7 | 0 | |
| General disorders and administration-site conditions | Fatigue | 35 | 3 | 27 | 6 |
| Pyrexia | 25 | 1 | 37 | 3 | |
| Edema Edema includes the following preferred terms: Eye edema, Eyelid edema, Face edema, Generalized edema, Localized edema, Edema, Edema peripheral, Penile edema, Periorbital edema, Periorbital swelling, Peripheral swelling, Scrotal edema, Scrotal swelling, Swelling, Swelling face, Swelling of eyelid, Testicular edema, Tongue edema. | 19 | <1 | 17 | 1 | |
| Chest pain Chest pain includes the following preferred terms: Chest discomfort, Chest pain. | 8 | 1 | 12 | 1 | |
| Hepatobiliary disorders | Hepatic dysfunction Hepatic dysfunction includes the following preferred terms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Bilirubin conjugated increased, Blood alkaline phosphatase increased, Blood bilirubin increased, Blood bilirubin unconjugated increased, Gamma-glutamyltransferase increased, Hepatic enzyme increased, Hepatic function abnormal, Hepatic steatosis, Hepatitis toxic, Hepatomegaly, Hepatotoxicity, Hyperbilirubinemia, Liver disorder, Liver function test abnormal, Liver function test increased, Transaminases increased. | 29 | 11 | 21 | 10 |
| Infections and infestations | Respiratory tract infection Respiratory tract infection includes the following preferred terms: Nasopharyngitis, Respiratory tract congestion, Respiratory tract infection, Respiratory tract infection viral, Upper respiratory tract infection, Viral upper respiratory tract infection. | 27 | <1 | 17 | 0 |
| Influenza Influenza includes the following preferred terms: H1N1 influenza, Influenza. | 11 | 1 | 3 | 0 | |
| Pneumonia Pneumonia includes the following preferred terms: Atypical pneumonia, Lower respiratory tract congestion, Lower respiratory tract infection, Pneumonia, Pneumonia aspiration, Pneumonia bacterial, Pneumonia fungal, Pneumonia necrotising, Pneumonia streptococcal. | 10 | 4 | 18 | 12 | |
| Respiratory, thoracic, and mediastinal disorders | Cough | 24 | 0 | 22 | 0 |
| Pleural effusion | 14 | 4 | 9 | 4 | |
| Dyspnea | 12 | 2 | 20 | 6 | |
| Nervous system disorders | Headache | 21 | 1 | 18 | 4 |
| Dizziness | 11 | 0 | 14 | 1 | |
| Musculoskeletal and connective tissue disorders | Arthralgia | 19 | 1 | 15 | 0 |
| Back pain | 14 | 1 | 8 | 1 | |
| Metabolism and nutrition disorders | Decreased appetite | 14 | 1 | 14 | 0 |
| Vascular disorders | Hypertension Hypertension* includes the following preferred terms: Blood pressure increased, Blood pressure systolic increased, Essential hypertension, Hypertension, Hypertensive crisis, Retinopathy hypertensive. ADR identified post-marketing | 11 | 3 | 8 | 3 |
| CP CML N=403 % | AdvP CML N=143 % | |||
|---|---|---|---|---|
| All grade | Grade 3/4 | All grade | Grade 3/4 | |
| Abbreviations: AdvP=advanced phase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CML=chronic myelogenous leukemia; CP=chronic phase; N/n=number of patients; SGPT=serum glutamate-pyruvate transaminase; SGOT=serum glutamate-oxaloacetate aminotransferase; ULN=upper limit of normal. | ||||
| Hematology Parameters | ||||
| Platelet Count decreased | 66 | 26 | 80 | 57 |
| Absolute Neutrophil Count decreased | 50 | 16 | 66 | 39 |
| Hemoglobin decreased | 89 | 13 | 97 | 38 |
| Lymphocyte decreased | 79 | 14 | 82 | 21 |
| White Blood Cell Count decreased | 51 | 7 | 57 | 27 |
| Biochemistry Parameters | ||||
| SGPT/ALT increased | 58 | 11 | 39 | 6 |
| SGOT/AST increased | 50 | 5 | 37 | 3.5 |
| Lipase increased | 32 | 12 | 19 | 6 |
| Phosphorus decreased | 41 | 8 | 33 | 7 |
| Total Bilirubin increased | 16 | 0.7 | 22 | 2.8 |
| Creatinine increased | 95 | 3 | 87 | 1.4 |
| Alkaline Phosphatase increased | 39 | 0 | 39 | 1.4 |
| Glucose increased | 42 | 2.7 | 39 | 6 |
| Sodium increased | 23 | 0.5 | 11 | 0 |
| Sodium decreased | 18 | 2.2 | 27 | 6 |
| Calcium decreased | 55 | 4.7 | 45 | 3.5 |
| Urate increased | 49 | 6 | 43 | 6 |
| Magnesium increased | 27 | 7 | 18 | 4.9 |
| Potassium decreased | 22 | 1.7 | 29 | 4.9 |
| Potassium increased | 25 | 2.7 | 19 | 2.1 |
| Adverse drug reactions are based on all-causality treatment-emergent adverse reactions. | |||
| The commonality stratification is based on 'All Grades' under Bosutinib 400 mg column. | |||
| 'Grade 3/4 columns indicate maximum toxicity. | |||
| System Organ Class | Preferred Term | BOSULIF Total (N=49) % | |
| All Grades | Grade 3/4 | ||
| Gastrointestinal disorders | Diarrhea | 82 | 12 |
| Abdominal pain Abdominal pain includes the following preferred terms: Abdominal discomfort, Abdominal pain, Abdominal pain lower, Abdominal pain upper, Abdominal tenderness, Dyspepsia, Epigastric discomfort, Gastrointestinal pain, Hepatic pain. | 73 | 4 | |
| Vomiting | 55 | 6 | |
| Nausea | 49 | 2 | |
| Constipation | 20 | 0 | |
| Skin and subcutaneous tissue disorders | Rash Rash includes the following preferred terms: Acarodermatitis, Acne, Angular cheilitis, Blister, Dermatitis, Dermatitis acneiform, Dermatitis bullous, Dermatitis exfoliative generalized, Dermatitis psoriasiform, Drug eruption, Drug reaction with eosinophilia and systemic symptoms, Dyshidrotic eczema, Eczema, Eczema asteatotic, Erythema, Erythema annulare, Erythema nodosum, Exfoliative rash, Genital rash, Lichen planus, Lichenoid keratosis, Palmar erythema, Palmar-plantar erythrodysesthesia syndrome, Perivascular dermatitis, Photosensitivity reaction, Pigmentation disorder, Pruritus allergic, Psoriasis, Punctate keratitis, Pyoderma gangrenosum, Pyogenic granuloma, Rash, Rash erythematous, Rash generalized, Rash macular, Rash maculo-papular, Rash papular, Rash pruritic, Rash pustular, Rash vesicular, Seborrheic dermatitis, Seborrhoeic keratosis, Skin depigmentation, Skin discoloration, Skin disorder, Skin exfoliation, Skin hyperpigmentation, Skin hypopigmentation, Skin irritation, Skin lesion, Skin plaque, Skin reaction, Skin toxicity, Stasis dermatitis. | 49 | 8 |
| Hepatobiliary disorders | Hepatic dysfunction Hepatic dysfunction includes the following preferred terms: Alanine aminotransferase abnormal, Alanine aminotransferase increased, Aspartate aminotransferase, Aspartate aminotransferase increased, Bilirubin conjugated increased, Blood alkaline phosphatase increased, Blood bilirubin increased, Blood bilirubin unconjugated increased, Gamma-glutamyltransferase increased, Hepatic enzyme increased, Hepatomegaly, Hepatosplenomegaly, Hyperbilirubinaemia, Jaundice, Liver function test abnormal, Liver function test increased, Ocular icterus, Transaminases increased, Hepatic function abnormal, Drug-induced liver injury, Hepatic steatosis, Hepatitis, Hepatitis toxic, Hepatobiliary disease, Hepatocellular injury, Hepatotoxicity, Liver disorder, Liver injury. | 37 | 14 |
| General disorders and administration-site conditions | Fatigue Fatigue includes the following preferred terms: Asthenia, Fatigue, Malaise. | 37 | 4 |
| Pyrexia | 31 | 4 | |
| Nervous system disorders | Headache | 35 | 2 |
| Metabolism and nutrition disorders | Decreased appetite | 27 | 2 |
| Infections and infestations | Respiratory tract infection Respiratory tract infection includes the following preferred terms: Nasopharyngitis, Respiratory tract congestion, Respiratory tract infection, Respiratory tract infection viral, Upper respiratory tract congestion, Upper respiratory tract infection, Upper respiratory tract inflammation, Viral upper respiratory tract infection. | 12 | 2 |
| Grades are defined using CTCAE V4.03. Based on CTCAE grading without regard to fasting status for 'Hyperglycemia' lab parameter. | ||
| Includes data up to 28 days after last dose of study treatment. | ||
| BOSULIF (N= 49) | ||
| All Grade | Grade 3/4 | |
| % | % | |
| Creatinine increased | 92 | 0 |
| Alanine aminotransferase increased | 59 | 14 |
| White blood cell count decreased | 53 | 4 |
| Aspartate aminotransferase increased | 51 | 6 |
| Platelet count decreased | 49 | 18 |
| Glucose increased | 41 | 0 |
| Calcium decreased | 31 | 0 |
| Hemoglobin decreased | 31 | 8 |
| Neutrophil count decreased | 31 | 12 |
| Lymphocyte count decreased | 29 | 2 |
| Serum amylase increased | 27 | 4 |
| CPK increased | 25 | 0 |
Warnings & Cautions for Bosulif
Gastrointestinal Toxicity
Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment. Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement. In the randomized clinical trial in adult patients with newly-diagnosed Ph+ CML, the median time to onset for diarrhea (all grades) was 4 days and the median duration per event was 3 days.
Among 546 adult patients in a single-arm study in patients with CML who were resistant or intolerant to prior therapy, the median time to onset for diarrhea (all grades) was 2 days and the median duration per event was 2 days. Among the patients who experienced diarrhea, the median number of episodes of diarrhea per patient during treatment with BOSULIF was 3 (range 1–268). Among 49 pediatric patients with newly-diagnosed CP Ph+ CML or who had CP Ph+ CML that was resistant or intolerant to prior therapy, the median time to onset for diarrhea (all grades) was 2 days and the duration was 2 days.
To manage gastrointestinal toxicity, withhold, dose reduce, or discontinue BOSULIF as necessary.
Myelosuppression
Thrombocytopenia, anemia and neutropenia occur with BOSULIF treatment. Perform complete blood counts weekly for the first month of therapy and then monthly thereafter, or as clinically indicated.
Hepatic Toxicity Bosutinib may cause elevations in serum transaminases (alanine aminotransferase, aspartate aminotransferase ). Two cases consistent with drug induced liver injury (defined as concurrent elevations in ALT or AST greater than or equal to 3×ULN with total bilirubin greater than 2×ULN and alkaline phosphatase less than 2×ULN) have occurred without alternative causes. This represented 2 out 1711 patients in BOSULIF clinical trials.
In the 268 adult patients from the safety population in the randomized clinical trial in patients with newly-diagnosed CML in the BOSULIF treatment group, the incidence of ALT elevation was 68.3% and increased AST was 56%. Of patients who experienced increased transaminases of any grade, 73% experienced their first increase within the first 3 months. Among the 546 adult patients in a single-arm study in patients with CML who were resistant or intolerant to prior therapy, the incidence of increased ALT was 53.3% and AST elevation was 46.7%.
Sixty percent of the patients experienced an increase in either ALT or AST. The median time to onset of increased ALT and AST was 22 and 29 days, respectively, and the median duration for each was 21 days. Among 49 pediatric patients with newly‑diagnosed CP Ph+ CML or who had CP Ph+ CML that was resistant or intolerant to prior therapy, the incidence based on laboratory data that worsened from baseline of increased ALT was 59% and of increased AST 51%.
Most cases of increased transaminases occurred early in treatment; of patients who experienced increased transaminases of any grade, 84% of patients experienced their first increases within the first 3 months. The median time to onset for adverse reactions of increased ALT and AST was 22 and 15 days, respectively. Perform hepatic enzyme tests monthly for the first 3 months of BOSULIF treatment and as clinically indicated.
In patients with transaminase elevations, monitor liver enzymes more frequently.
Cardiovascular Toxicity BOSULIF can cause cardiovascular toxicity including cardiac failure, left ventricular dysfunction, and cardiac ischemic events. Cardiac failure events occurred more frequently in previously treated patients than in patients with newly diagnosed CML and were more frequent in patients with advanced age or risk factors, including previous medical history of cardiac failure. Cardiac ischemic events occurred in both previously treated patients and in patients with newly diagnosed CML and were more common in patients with coronary artery disease risk factors, including history of diabetes, body mass index greater than 30, hypertension, and vascular disorders.
In a randomized study of adult patients with newly diagnosed CML, cardiac failure occurred in 1.9% of patients treated with BOSULIF compared to 0.8% of patients treated with imatinib. Cardiac ischemic events occurred in 4.9% of patients treated with BOSULIF compared to 0.8% of patients treated with imatinib. In a single-arm study in adult patients with CML who were resistant or intolerant to prior therapy, cardiac failure was observed in 5.3% of patients and cardiac ischemic events were observed in 5.1% of patients treated with BOSULIF.
Among 49 pediatric patients with newly diagnosed CP Ph+ CML or who had CP Ph+ CML that was resistant or intolerant to prior therapy, 4 (8%) patients had Grade 1-2 cardiac events, including tachycardia (n=2), angina pectoris, right bundle branch block, and sinus tachycardia (n=1 each). Monitor patients for signs and symptoms consistent with cardiac failure and cardiac ischemia and treat as clinically indicated. Interrupt, dose reduce, or discontinue BOSULIF as necessary.
Fluid Retention
Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema. Some patients experienced more than one fluid retention event. Among 49 pediatric patients with newly diagnosed CP Ph+ CML or who had CP Ph+ CML that was resistant or intolerant to prior therapy, Grade 1-2 pericardial effusion, peripheral edema, and face edema were reported in 1 patient each.
Renal Toxicity
An on-treatment decline in estimated glomerular filtration rate (eGFR) has occurred in patients treated with BOSULIF. Table 6 identifies the shift from baseline to lowest observed eGFR during BOSULIF therapy for patients in the pooled leukemia studies regardless of line of therapy. The median duration of therapy with BOSULIF was approximately 24 months (range, 0.03 to 155) for patients in these studies.
Table 6: Shift From Baseline to Lowest Observed eGFR Group During Treatment Safety Population in Clinical Studies (N=1372) Among the 1372 patients, eGFR was missing in 7 patients at baseline or on-therapy. There were no patients with kidney failure at baseline. Overall, 45% of the pediatric patients with newly diagnosed CP Ph+ CML or resistant or intolerant CP Ph+ CML who had normal eGFR at baseline shifted to a maximum of mild, and 40% pediatric patients who had mild eGFR at baseline shifted to a maximum of moderate during treatment.
Monitor renal function at baseline and during therapy with BOSULIF, with particular attention to those patients who have preexisting renal impairment or risk factors for renal dysfunction. Consider dose adjustment in patients with baseline and treatment emergent renal impairment.
Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, BOSULIF can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies conducted in rats and rabbits, oral administration of bosutinib during organogenesis caused adverse developmental outcomes, including structural abnormalities, embryo-fetal mortality, and alterations to growth at maternal exposures (AUC) as low as 1.2 times the human exposure at the dose of 500 mg/day.
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose.
| Baseline | Follow-Up | ||||||
|---|---|---|---|---|---|---|---|
| Abbreviations: eGFR=estimated glomerular filtration rate; N/n=number of patients. Notes: eGFR was calculated using Modification in Diet in Renal Disease method (MDRD). Notes: Grading is based on Kidney Disease Improving Global Outcomes (KDIGO) Classification by eGFR: Normal: greater than or equal to 90, Mild: 60 to less than 90, Mild to Moderate: 45 to less than 60, Moderate to Severe: 30 to less than 45, Severe: 15 to less than 30, Kidney Failure: less than 15 ml/min/1.73 m 2. | |||||||
| Renal Function Status | N | Normal n (%) | Mild n (%) | Mild to Moderate n (%) | Moderate to Severe n (%) | Severe n (%) | Kidney Failure n (%) |
| Normal | 527 | 115 (21.8) | 330 (62.6) | 50 (9.5) | 23 (4.4) | 3 (0.6) | 5 (0.9) |
| Mild | 672 | 10 (1.5) | 259 (38.5) | 271 (40.3) | 96 (14.3) | 26 (3.9) | 6 (0.9) |
| Mild to Moderate | 137 | 0 | 6 (4.4) | 40 (29.2) | 66 (48.2) | 24 (17.5) | 1 (0.7) |
| Moderate to Severe | 33 | 0 | 1 (3.0) | 1 (3.0) | 8 (24.2) | 19 (57.6) | 4 (12.1) |
| Severe | 1 | 0 | 0 | 0 | 0 | 0 | 1 (100) |
| Total | 1370 | 125 (9.1) | 596 (43.5) | 362 (26.4) | 193 (14.1) | 72 (5.2) | 17 (1.2) |
Drug Interactions with Bosulif
Effect of Other Drugs on BOSULIF Strong or Moderate CYP3A Inhibitors Avoid the concomitant use of strong or moderate CYP3A inhibitors with BOSULIF. Bosutinib is a CYP3A substrate. Concomitant use with a strong or moderate CYP3A inhibitor increases bosutinib C max and AUC which may increase the risk of toxicities.
Concomitant use with a strong CYP3A inducer decreases bosutinib C max and AUC which may reduce BOSULIF efficacy. Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. Bosutinib displays pH dependent aqueous solubility, Concomitant use with a PPI decreases bosutinib C max and AUC which may reduce BOSULIF efficacy.
Pregnancy Safety for Bosulif
Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, BOSULIF can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies conducted in rats and rabbits, oral administration of bosutinib during organogenesis caused adverse developmental outcomes, including structural abnormalities, embryo-fetal mortality, and alterations to growth at maternal exposures (AUC) as low as 1.2 times the human exposure at the dose of 500 mg/day ( see Data ).
Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2–4% and 15–20%, respectively. Data Animal Data In a rat fertility and early embryonic development study, bosutinib was administered orally to female rats for approximately 3 to 6 weeks, depending on day of mating (2 weeks prior to cohabitation with untreated breeder males until gestation day 7). In an embryo-fetal development study conducted in rabbits, bosutinib was administered orally to pregnant animals during the period of organogenesis at doses of 3, 10, and 30 mg/kg/day.
At the maternally-toxic dose of 30 mg/kg/day of bosutinib, there were fetal anomalies (fused sternebrae, and 2 fetuses had various visceral observations), and an approximate 6% decrease in fetal body weight. Fetal exposure to bosutinib-derived radioactivity during pregnancy was demonstrated in a placental-transfer study in pregnant rats.
Pediatric Use of Bosulif
Pediatric Use The safety and effectiveness of BOSULIF have been established in pediatric patients 1 year of age and older with newly-diagnosed CP Ph+ CML and CP Ph+ CML that is resistant or intolerant to prior therapy. Use of BOSULIF for these indications is based on data from BCHILD. The recommended dosage of BOSULIF in pediatric patients is based on body surface area (BSA).
Contraindications for Bosulif
BOSULIF is contraindicated in patients with a history of hypersensitivity to BOSULIF. Reactions have included anaphylaxis. Hypersensitivity to BOSULIF.
Overdosage Information for Bosulif
Experience with BOSULIF overdose in clinical studies was limited to isolated cases. There were no reports of any serious adverse events associated with the overdoses. Patients who take an overdose of BOSULIF should be observed and given appropriate supportive treatment.
Clinical Studies of Bosulif
Adult Patients with Newly-Diagnosed CP Ph+ CML
The efficacy of BOSULIF in patients with newly-diagnosed chronic phase Ph+ CML was evaluated in the B osutinib trial in F irst-line chr O nic myelogenous leukemia t RE atment (BFORE) Trial: "A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia". The BFORE Trial is a 2-arm, open-label, randomized, multicenter trial conducted to investigate the efficacy and safety of BOSULIF 400 mg once daily alone compared with imatinib 400 mg once daily alone in adult patients with newly-diagnosed CP Ph+ CML. The trial randomized 536 patients (268 in each arm) with Ph+ or Ph- newly-diagnosed CP CML (intent-to-treat population) including 487 patients with Ph+ CML harboring b2a2 and/or b3a2 transcripts at baseline and baseline BCR-ABL copies >0 (modified intent-to-treat population).
Randomization was stratified by Sokal score and geographical region. All patients are being treated and/or followed for up to 5 years (240 weeks). Efficacy was evaluated in the mITT population.
The major efficacy outcome measure was major molecular response (MMR) at 12 months (48 weeks) defined as ≤0.1% BCR-ABL ratio on international scale (corresponding to ≥3 log reduction from standardized baseline) with a minimum of 3000 ABL transcripts as assessed by the central laboratory. Additional efficacy outcomes included CCyR by 12 months, defined as the absence of Ph+ metaphases in chromosome banding analysis of ≥20 metaphases derived from bone marrow aspirate or MMR if an adequate cytogenetic assessment was unavailable and MMR by 18 months (72 weeks). The median age was 53 years.
The median treatment duration was 55.1 months for BOSULIF and 55.0 months for imatinib. The efficacy results from the BFORE trial are summarized in Table 13. Table 13: Summary of Major Molecular Response (MMR) and Complete Cytogenetic Response (CCyR), by Treatment Group in the Modified Intent-to-Treat (mITT) Population The MMR rate at Month 12 for all randomized patients (ITT population) was consistent with the mITT population (47% in the bosutinib treatment group and 36% in the imatinib treatment group; odds ratio of 1.57 ).
MMR by Month 60 (Week 240) in the mITT population was in the bosutinib treatment group and in the imatinib treatment group; odds ratio of MMR by Month 60 in the ITT population was also consistent with the mITT population. After 60 months of follow-up, the median time to MMR in responders was 9.0 months for bosutinib and 11.9 months for imatinib. At 60 months, the estimated overall survival rate was in the bosutinib group and in the imatinib group.
Adult Patients with Imatinib-Resistant or -Intolerant Ph+ CP, AP, and BP CML Study 200 (NCT00261846), a single-arm, open-label, multicenter study in patients with CML who were resistant or intolerant to prior therapy was conducted to evaluate the efficacy and safety of BOSULIF 500 mg once daily in patients with imatinib-resistant or -intolerant CML with separate cohorts for CP, AP, and BP disease previously treated with 1 prior TKI (imatinib) or more than 1 TKI (imatinib followed by dasatinib and/or nilotinib). The definition of imatinib resistance included failure to achieve or maintain any hematologic improvement within 4 weeks; failure to achieve a CHR by 3 months, cytogenetic response by 6 months or major cytogenetic response (MCyR) by 12 months; progression of disease after a previous cytogenetic or hematologic response; or presence of a genetic mutation in the BCR-ABL gene associated with imatinib resistance. Imatinib intolerance was defined as inability to tolerate imatinib due to toxicity, or progression on imatinib and inability to receive a higher dose due to toxicity.
The definitions of resistance and intolerance to both dasatinib and nilotinib were similar to those for imatinib. The protocol was amended to exclude patients with a known history of the T315I mutation after 396 patients were enrolled in the trial. The efficacy endpoints for patients with CP CML previously treated with 1 prior TKI (imatinib) were the rate of attaining MCyR by Week 24 and the duration of MCyR.
The efficacy endpoints for patients with previously treated AP and BP CML were confirmed CHR and overall hematologic response (OHR). The study enrolled 546 patients with CP, AP or BP CML. Of the total patient population 73% were imatinib resistant and 27% were imatinib intolerant.
Of the 546 treated patients, 506 were considered evaluable for cytogenetic or hematologic efficacy assessment. Patients were evaluable for efficacy if they had received at least 1 dose of BOSULIF and had a valid baseline efficacy assessment. Median duration of BOSULIF treatment was 26 months in patients with CP CML previously treated with 1 TKI (imatinib), 9 months in patients with CP CML previously treated with imatinib and at least 1 additional TKI, 10 months in patients with AP CML previously treated with at least imatinib, and 3 months in patients with BP CML previously treated with at least imatinib.
The 24 week efficacy and MCyR at any time results are summarized in Table 14. Table 14: Efficacy Results in Patients with Ph+ CP CML With Resistance to or Intolerance to Imatinib 156 45 The long-term follow-up data analysis was based on a minimum of 60 months for patients with CP CML treated with 1 prior TKI (imatinib) and a minimum of 48 months for patients with CP CML treated with imatinib and at least 1 additional TKI. For the 59.5% of patients with CP CML treated with 1 prior TKI (imatinib) who achieved a MCyR at any time, the median duration of MCyR was not reached.
For the 40.2% of patients with CP CML treated with imatinib and at least 1 additional TKI who achieved a MCyR at any time, the median duration of MCyR was not reached. Of the 403 treated patients with CP CML, 20 patients had confirmed disease transformation to AP or BP while on treatment with BOSULIF. The 48-week efficacy results in patients with accelerated and blast phases CML previously treated with at least imatinib are summarized in Table 15.
Table 15: Efficacy Results in Patients With Accelerated Phase and Blast Phase CML Previously Treated With at Least Imatinib The long-term follow-up data analysis was based on a minimum of 48 months for patients with AP CML and BP CML. Of the 79 treated patients with AP CML, 3 patients had confirmed disease transformation to BP while on BOSULIF treatment.
Pediatric Patients with Newly-Diagnosed CP Ph+ CML or with CP Ph+ CML with Resistance or Intolerance to Prior Therapy The efficacy of BOSULIF in pediatric patients with newly-diagnosed (ND) chronic phase (CP) Ph+ CML and patients with resistant/intolerant (R/I) CP Ph+ CML was evaluated in the BCHILD trial. The BCHILD trial is a multicenter, non-randomized, open-label study conducted to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with ND CP Ph+ CML and pediatric patients with R/I CP Ph+ CML who have received at least one prior TKI therapy, to estimate the safety and tolerability and efficacy, and to evaluate the PK of bosutinib in this patient population. Efficacy outcomes included CCyR (defined as the absence of Ph+ metaphases in chromosome banding analysis of ≥20 metaphases, or <1% BCR-ABL1–positive nuclei of at least 200 peripheral blood interphase nuclei analyzed by Fluorescence In Situ Hybridization (FISH), or MMR if an adequate cytogenetic assessment was unavailable), MCyR (defined as CCyR or partial cytogenetic response of 1% to 35% Ph+ metaphases), and MMR (defined as ≤0.1% BCR-ABL ratio on international scale ) at any time on study.
The major (MCyR) and complete (CCyR) cytogenetic responses among patients with ND CP Ph+ CML were respectively. The MMR among patients with ND CP Ph+ CML was The median duration of follow-up was 14.2 months (range: 1.1, 26.3 months) in patients with ND CP CML. The MMR among patients with R/I CP Ph+ CML was The MR4.5 defined as BCR-ABL/ABL IS ≤ Among 14 patients who achieved MMR, two patients lost MMR after 13.6 months and 24.7 months on treatment.
The median duration of follow-up for overall survival was 23.2 months (range: 1.0, 61.5 months) in patients with R/I CP Ph+ CML.
| Response | Bosutinib N=246 n (%) | Imatinib N=241 n (%) | 2-sided p-value |
|---|---|---|---|
| Abbreviations: CCyR=complete cytogenetic response; CI=confidence interval; CMH=Cochran-Mantel-Haenszel; MMR=major molecular response; N/n=number of patients. | |||
| MMR at Month 12 (Week 48) | |||
| MMR (%) | 116 (47) | 89 (37) | 0.0200 Derived from CMH test stratified by Geographical region and Sokal score at randomization. |
| (95% CI) | (41, 53) | (31, 43) | |
| CCyR by Month 12 (Week 48) | |||
| CCyR (%) | 190 (77) | 160 (66) | |
| (95% CI) | (72, 83) | (60, 72) | 0.0075 |
| MMR by Month 18 (Week 72) | |||
| MMR (%) | 150 (61) | 127 (53) | |
| (95% CI) | (55, 67) | (46, 59) | 0.0606 |
| Prior Treatment With Imatinib Only (N=262 evaluable) n (%) | Prior Treatment With Imatinib and Dasatinib or Nilotinib (N=112 evaluable) n (%) | |
|---|---|---|
| Abbreviations: CI=confidence interval; CML=chronic myelogenous leukemia; CP=chronic phase; MCyR=major cytogenetic response; N/n=number of patients; Ph+=Philadelphia chromosome positive. | ||
| By Week 24 | ||
| MCyR | 105 (40.1) | 29 (25.9) |
| (95% CI) | (34.1, 46.3) | (18.1, 35.0) |
| MCyR any time | 156 (59.5) | 45 (40.2) |
| (53.3, 65.5) | (31.0, 49.9) | |
| AP CML (N=72 evaluable) n (%) | BP CML (N=60 evaluable) n (%) | |
|---|---|---|
| Abbreviations: AP=accelerated phase; BP=blast phase; CHR=complete hematologic response; CI=confidence interval; CML=chronic myelogenous leukemia; CI=confidence interval, OHR=overall hematologic response, CHR=complete hematologic response, N/n=number of patients | ||
| CHR Overall hematologic response (OHR) = major hematologic response (complete hematologic response + no evidence of leukemia) or return to chronic phase (RCP). All responses were confirmed after 4 weeks. Complete hematologic response (CHR) for AP and BP CML: WBC less than or equal to institutional ULN, platelets greater than or equal to 100,000/mm 3 and less than 450,000/mm 3, absolute neutrophil count (ANC) greater than or equal to 1.0×10 9 /L, no blasts or promyelocytes in peripheral blood, less than 5% myelocytes + metamyelocytes in bone marrow, less than 20% basophils in peripheral blood, and no extramedullary involvement. No evidence of leukemia (NEL): Meets all other criteria for CHR except may have thrombocytopenia (platelets greater than or equal to 20,000/mm 3 and less than 100,000/mm 3 ) and/or neutropenia (ANC greater than or equal to 0.5×10 9 /L and less than 1.0×10 9 /L). Return to chronic phase (RCP) = disappearance of features defining accelerated or blast phases but still in chronic phase. by Week 48 | 22 (30.6) | 10 (16.7) |
| (95% CI) | (20.2, 42.5) | (8.3, 28.5) |
| OHR by Week 48 | 41 (56.9) | 17 (28.3) |
| (95% CI) | (44.7, 68.6) | (17.5, 41.4) |
Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.
Ready to save on Bosulif?
Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.
Compare Bosulif Prices